TCGA-34-5240-01A-01R-1443-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.520
- MYC_TARGETS_V1+0.510
- OXIDATIVE_PHOSPHORYLATION+0.500
- PROTEIN_SECRETION+0.460
- MTORC1_SIGNALING+0.410
- CHOLESTEROL_HOMEOSTASIS+0.390
- DNA_REPAIR+0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- PANCREAS_BETA_CELLS+0.320
- UNFOLDED_PROTEIN_RESPONSE+0.320
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.370
- INTERFERON_GAMMA_RESPONSE-0.330
- IL6_JAK_STAT3_SIGNALING-0.310
- ALLOGRAFT_REJECTION-0.280
- WNT_BETA_CATENIN_SIGNALING-0.280
- HEDGEHOG_SIGNALING-0.260
- ANGIOGENESIS-0.250
- INFLAMMATORY_RESPONSE-0.250
- TNFA_SIGNALING_VIA_NFKB-0.240
- APICAL_SURFACE-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516095 | — | — | 0.883 |
| 2 | TCGA-21-1075-01A-01R-0692-07 | — | cohortSQ2 | 0.882 |
| 3 | TCGA-66-2766-01A-01R-0851-07 | — | cohortSQ2 | 0.865 |
| 4 | MNG69 | — | — | 0.862 |
| 5 | TCGA-DQ-7588-01A-11R-2081-07 | — | — | 0.853 |
| 6 | MDT-AP-0322 | Med | Medulloblastoma | 0.847 |
| 7 | MNG93 | — | — | 0.847 |
| 8 | s0112308 | — | — | 0.846 |
| 9 | TCGA-46-3768-01A-01R-0980-07 | — | cohortSQ2 | 0.842 |
| 10 | SRR10900021 | — | — | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.460 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.390 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| HYPOXIA | 0.140 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |